National and Kapodistrian University of Athens
Επίπεδα της χυμοκίνης MCP-1 (monocyte chemoattractant protein-1) σε νεφροπαθείς αιμοκαθαιρόμενους και υπό περιτοναϊκή κάθαρση ασθενείς: δείκτης αθηροσκλήρυνσης;
Abstract
dc:descriptionTITLE : MCP-1 (monocyte chemoattractant protein-1) levels in patients on hemodialysis and peritoneal dialysis.Is it a biomarker of atherosclerosis ? INTRODUCTION – AIM During the renal replacement therapies the circulating leukocytes are activated. The action of the monocyte chemoattractant protein-1 (MCP-1) involves effects other than as purely a chemoattractant for monocytes.It plays a particular role on the lessions of atherogenesis. The aim of the present study was to examine the MCP-1 kinetic in patients on permanent renal replacement therapies (hemodialysis and peritoneal dialysis) and its role as a biomarker of atherosclerosis.SUBJECTS – METHODS We studied 96 patients in a programme of permanent renal replacement therapy, 62 males and 34 females, on mean age 62.114.27 years old and 24 healthy subjects. The treatment modalities which were applied were : regular haemodialysis (HD, n=34), predilution haemodiafiltration (n=42, using bagged substitution fluid, HDF, n=19 and online-predilution haemodiafiltration, ON-L, n=23) and peritoneal dialysis (PD, n=20).Dialysis adequacy was defined by Kt/V for urea. Clinical manifestations of atherosclerosis were defined by coronary disease and the existence of peripheral vascular disease and left ventricular hypertrophy and heart failure were also estimated. Blood was drawn in a fasting state and the concentration of serum MCP-1 were measured using ELISA.In haemodialyzed patients 4 blood samples were drawn (pre-hemodialysis, 2 hours, 4 hours and 44 hours after the beginning of the mean weekly dialysis session).High sensitivity C-reactive protein (hsCRP) and tumor necrosis factor-α (ΤΝF-α) levels were also measured by ΕLISA, but beta 2-microglobulin, insulin, intact parathormone (i-PTH) and leptin levels were measured by radioimmunoassay. Insulin resistance was calculated using the homeostasis model assessment of insulin resistance (HOMA-IR). Uric acid, alkaline phosphate, albumin, cholesterol, triglycerides, high density lipoproteins levels were measured by biochemical analysis and the ratio total cholesterol / HDL was also calculated.Arterial stiffness was calculated as carotid-femoral pulse wave velocity (c-f PWV) and carotid augmentation index (AIx) using the SphygmoCor system® .Additionally, ankle-brachial blood pressure index (ABPI) was calculated. We built a logistic regression analysis to check the impact of MCP-1 concentrations on the existence of coronary disease, heart failure, left ventricular hypertrophy and peripheral vascular disease.RESULTS The mean value of MCP-1 was not found higher in comparison to control group (p=NS), either significant difference was noted among the following dialysis modalities. In the hemodialysis group of patients we observed that the mean value of MCP-1 of the second blood sample was significantly lower than the mean value of the pre-dialysis blood sample (p=0.001).However, the mean value of the third blood sample did not differ from the first sample, either from the fourth blood sample.Neverthless, the mean value of the third blood sample was significantly higher than the mean value of the second blood sample (p=0.001).The mean value of the fourth blood sample was significantly lower than the mean value of the first blood sample (p=0.012) and significantly higher than the mean value of the second blood sample (p=0.012). Additionally, significant correlation was found between the existence of left ventricular hypertrophy and the group of patients with the increased values of MCP-1 (x2 =4.233, p=0.032). In the logistic regression analysis we did not find any significant correlation between the values of MCP-1 and the existence of the coronary disease or heart failure.However, the MCP-1 levels were significantly associated with the existence of the peripheral vascular disease (B=0.004, OR=1.004, 95% CI 1.000-1.007, p=0.033) independently on confounders. The bivariate non-parametric correlations showed significantly positive correlation between MCP-1 and the ratio total cholesterol / HDL (r=0.303, p=0.003).The bivariate parametric correlations showed significantly positive correlation between MCP-1 and insulin levels and also between MCP-1 and body mass index (r=0.212, p=0.03 and r=0.242, p=0.017 respectively).CONCLUSIONS The findings of the present study show that MCP-1 serum concentrations in stabled patients on permanent renal replacement therapies are significantly changed during the process of renal replacement therapies and they can be characterized as a biomarker for vascular inflammation, rather than as a biomarker for atherosclerosis.To the known underlined mechanisms for the role of MCP-1 in the development of atherosclerosis, we could add the metabolic alterations, which may be a connective ring between MCP-1 levels and increased beta2-microglobulin levels, that are seen in this population of patients.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Raikou, Vaia
- Ράικου, Βάϊα
Subjects
dc:subject × 20- Αιμοκάθαρση
- Περιτοναϊκή κάθαρση
- Φλεγμονές
- Μεταβολισμός
- Κυτταροκίνες
- Αθηροσκλήρυνση
- Χυμοκίνες
- Καρδιαγγειακή νόσος
- Hemodialysis
- Peritoneal dialysis
- Inflammation
- Metabolism
- Cytokines
- Chemokines
- Atherosclerosis
- Cardiovascular disease
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29664